{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:33:27Z","timestamp":1789662807769,"version":"4.0.1"},"reference-count":37,"publisher":"SAGE Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2016,12,6]]},"DOI":"10.3233\/jad-160733","type":"journal-article","created":{"date-parts":[[2016,11,15]],"date-time":"2016-11-15T10:39:27Z","timestamp":1479206367000},"page":"1285-1294","source":"Crossref","is-referenced-by-count":49,"title":["Cholinesterase Inhibitor Therapy in Alzheimer\u2019s Disease: The Limits and Tolerability of Irreversible CNS-Selective Acetylcholinesterase Inhibition in Primates"],"prefix":"10.1177","volume":"55","author":[{"given":"Donald E.","family":"Moss","sequence":"first","affiliation":[{"name":"Department of Psychology, University of Texas at El Paso, El Paso, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth G.","family":"Perez","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Center of Emphasis in Neurosciences, Graduate School of Biomedical Sciences, Paul L. Foster School of Medicine, Texas Tech University of the Health Sciences El Paso, El Paso, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruo","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Veterinary Pharmacology, Iwate University, Ueda, Morioka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-160733_ref1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3233\/JAD-150381","article-title":"Treatment of Alzheimer\u2019s disease: The legacy of the cholinergic hypothesis, neuroplasticity, and future directions","volume":"47","author":"Ashford","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-160733_ref2","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(76)91936-X","article-title":"Selective loss of cholinergic neurons in Alzheimer\u2019s disease","volume":"2","author":"Davies","year":"1976","journal-title":"Lancet"},{"key":"10.3233\/JAD-160733_ref3","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/ana.410100203","article-title":"Alzheimer\u2019s disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis","volume":"10","author":"Whitehouse","year":"1981","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-160733_ref4","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1126\/science.7046051","article-title":"The cholinergic hypothesis of geriatric memory dysfunction","volume":"217","author":"Bartus","year":"1982","journal-title":"Science"},{"key":"10.3233\/JAD-160733_ref5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1310\/tsr1501-22","article-title":"Vascular dementia","volume":"15","author":"Schneck","year":"2008","journal-title":"Top Stroke Rehab"},{"key":"10.3233\/JAD-160733_ref6","first-page":"CD004744","article-title":"Rivastigmine for vascular cognitive impairment","author":"Birks","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.3233\/JAD-160733_ref7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.brainres.2005.01.028","article-title":"Methanesulfonyl fluoride, an acetylcholinesterase inhibitor, attenuates simple learning and memory deficits in ischemic rats","volume":"1038","author":"Borlongan","year":"2005","journal-title":"Brain Res"},{"key":"10.3233\/JAD-160733_ref8","first-page":"CD006504","article-title":"Cholinsterase inhibitors for dementia with Lewy bodies, Parkinson\u2019s disease dementia and cognitive impairment in Parkinson\u2019s disease","author":"Rolinski","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.3233\/JAD-160733_ref9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1136\/jnnp-2014-307659","article-title":"Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson\u2019s disease, Parkinson\u2019s disease dementia, and dementia with Lewy bodies: Systematic review with meta-analysis and trial sequential analysis","volume":"86","author":"Wang","year":"2015","journal-title":"J Neurol Neurosurg Psychia"},{"key":"10.3233\/JAD-160733_ref10","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0197-4580(93)90127-W","article-title":"Chronic methanesulfonyl fluoride enhances one-trial per day reward learning in aged rats","volume":"14","author":"Malin","year":"1993","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-160733_ref11","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.2174\/138161206778792985","article-title":"Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors","volume":"12","author":"Castro","year":"2006","journal-title":"Curr Pharmaceutical Des"},{"issue":"Suppl 1","key":"10.3233\/JAD-160733_ref12","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1097\/01.wad.0000213802.74434.d6","article-title":"Preclinical evidence of neuroprotection by cholinesterase inhibitors","volume":"20","author":"Akaike","year":"2006","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"Suppl 1","key":"10.3233\/JAD-160733_ref13","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1097\/01.wad.0000213804.59187.2d","article-title":"Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease","volume":"20","author":"Nordberg","year":"2006","journal-title":"Alz Dis Assoc Dis"},{"key":"10.3233\/JAD-160733_ref14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2174\/1568013033358635","article-title":"Immunotoxin lesion of the cholinergic nucleus basalis causes A\u03b2 deposition: Towards a physiologic animal model of Alzheimer\u2019s disease","volume":"3","author":"Beach","year":"2003","journal-title":"Curr Med Chem Immunol Endocr Metab Agents"},{"issue":"Suppl 1","key":"10.3233\/JAD-160733_ref15","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/01.wad.0000127495.10774.a4","article-title":"Long-term treatment of Alzheimer disease: Efficacy and safety of acetylcholinesterase inhibitors","volume":"18","author":"Winblad","year":"2004","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.3233\/JAD-160733_ref16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/WAD.0b013e31816653bc","article-title":"Long-term course and effectiveness of combination therapy in Alzheimer\u2019s disease","volume":"22","author":"Atri","year":"2008","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.3233\/JAD-160733_ref17","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/alzrt280","article-title":"Treatment effects in multiple cognitive domains in Alzheimer\u2019s disease: A two-year cohort study","volume":"6","author":"Behl","year":"2014","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-160733_ref18","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1124\/mol.107.033928","article-title":"The kinetics of inhibition of human acetylcholinesterase and butyrylcholinesterase by two series of novel carbamates","volume":"71","author":"Groner","year":"2007","journal-title":"Mol Pharmacol"},{"key":"10.3233\/JAD-160733_ref19","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/00023210-200115050-00004","article-title":"Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer\u2019s disease","volume":"15","author":"Imbimbo","year":"2001","journal-title":"CNS Drugs"},{"key":"10.3233\/JAD-160733_ref20","first-page":"305","volume-title":"Current Research in Alzheimer Therapy","author":"Moss","year":"1988"},{"key":"10.3233\/JAD-160733_ref21","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1248\/jhs.45.191","article-title":"Effects of a central anticholinesterase, methanesulfonyl fluoride on the cerebral cholinergic system and behavior in mice: Comparison with an organophosphate DDVP","volume":"45","author":"Kobayashi","year":"1999","journal-title":"J Health Sci"},{"key":"10.3233\/JAD-160733_ref22","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/00002093-199601030-00003","article-title":"Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease","volume":"10","author":"Becker","year":"1996","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.3233\/JAD-160733_ref23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF00351767","article-title":"Transformation and action of metrifonate","volume":"41","author":"Nordgren","year":"1978","journal-title":"Arch Toxicol"},{"key":"10.3233\/JAD-160733_ref24","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/0028-3908(87)90143-2","article-title":"A comparison of two inhibitors on brain cholinesterase","volume":"26","author":"Hallak","year":"1987","journal-title":"Neuropharmacol"},{"key":"10.3233\/JAD-160733_ref25","doi-asserted-by":"crossref","first-page":"29718","DOI":"10.1074\/jbc.M111.264739","article-title":"Oxime-assisted acetylcholinesterase catalytic scavengers of organophosphates that resist aging","volume":"286","author":"Cochran","year":"2011","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-160733_ref26","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1016\/S0021-9258(18)50153-8","article-title":"Esters of methanesulfonic acid as irreversible inhibitors of acetycholinesterase","volume":"237","author":"Kitz","year":"1962","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-160733_ref27","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1006\/faat.1996.0167","article-title":"Sulfonyl fluorides and the promotion of diisopropyl fluorophosphates neuropathy","volume":"33","author":"Osman","year":"1996","journal-title":"Fund Appl Toxicol"},{"key":"10.3233\/JAD-160733_ref28","first-page":"CD003155","article-title":"Metrifonate for Alzheimer\u2019s disease","author":"Lopez-Arrieta","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.3233\/JAD-160733_ref29","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.pharmthera.2012.03.001","article-title":"Functional consequences of repeated organophosphate exposure: Potential non-cholinergic mechanisms","volume":"134","author":"Terry","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.3233\/JAD-160733_ref30","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/bcp.12018","article-title":"A randomized Phase I study of methanesulfonyl fluoride, an irreversible acetylcholinesterse inhibitor, for the treatment of Alzheimer\u2019s disease","volume":"75","author":"Moss","year":"2013","journal-title":"Brit J Clin Pharmacol"},{"key":"10.3233\/JAD-160733_ref31","first-page":"708108","article-title":"Effects of a CNS sensitive anticholinesterase methane sulfonyl fluoride on hippocampal acetylcholine release in freely moving rats","volume":"2012","author":"Imanishi","year":"2012","journal-title":"Adv Pharmacol Sci"},{"key":"10.3233\/JAD-160733_ref32","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/00002093-199903000-00003","article-title":"Methanesulfonyl fluoride (MSF): A double-blind, placebo-controlled study of the safety and efficacy in the treatment of senile dementia of the Alzheimer type","volume":"13","author":"Moss","year":"1999","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.3233\/JAD-160733_ref33","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0006-2952(61)90145-9","article-title":"A new and rapid colorimetric determination of acetylcholinesterase","volume":"7","author":"Ellman","year":"1961","journal-title":"Biochem Pharmacol"},{"key":"10.3233\/JAD-160733_ref34","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1021\/tx00006a009","article-title":"A chemical comparison of methanesulfonyl fluoride with organofluorophosphorus ester anticholinesterase compounds","volume":"1","author":"Snow","year":"1988","journal-title":"Chem Res Toxicol"},{"key":"10.3233\/JAD-160733_ref35","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0022-3565(25)10622-8","article-title":"Cholinesterase inhibitors proposed for the treatment of Alzheimer\u2019s Disease: Selectivity toward human brain acetylcholinesterase compared to butyrylcholinesterase","volume":"274","author":"Pacheco","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.3233\/JAD-160733_ref36","first-page":"47","article-title":"Factors that accelerate or retard red blood cell senescense","volume":"14","author":"Landaw","year":"1988","journal-title":"Blood Cells"},{"key":"10.3233\/JAD-160733_ref37","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1358\/mf.2000.22.1.795849","article-title":"The recovery of cerebrospinal fluid acetylcholinesterase activity in Alzheimer\u2019s disease patients after treatment with metrifonate","volume":"22","author":"Unni","year":"2000","journal-title":"Meth Find Exp Clin Pharmacol"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-160733","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:04:26Z","timestamp":1777370666000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-160733"}},"subtitle":[],"editor":[{"given":"Taher","family":"Darreh-Shori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,12,6]]},"references-count":37,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/jad-160733","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,6]]}}}